📣 VC round data is live. Check it out!

SyntekaBio Valuation Multiples

Discover revenue and EBITDA valuation multiples for SyntekaBio and similar public comparables like Isofol Medical, Longeveron, Gensight Biologics, Pluri and more.

SyntekaBio Overview

About SyntekaBio

SyntekaBio Inc is a bioinformatics venture firm. It is engaged in gene-related research, technology development, and genetic analysis based on the genome big data platform and artificial intelligence deep learning drug development platform. The company manages and analyzes genome analysis and massive biodata and genome.


Founded

2009

HQ

South Korea

Employees

41

Financials (LTM)

Revenue: $3M
Net Income: ($7M)

EV

$21M

Valuation Multiples

Start free trial

Valuation Multiples for 15K+ Public Comps

AdidasAirbnbAmazonCiscoCoca-ColaDellDropboxIBMIntelMcDonaldsNikeNVIDIASamsungSpotifyTeslaToyota
Browse Valuation Multiples

SyntekaBio Financials

SyntekaBio reported last 12-month revenue of $3M.

In the same LTM period, SyntekaBio generated had net loss of ($7M).

Revenue (LTM)


SyntekaBio P&L

In the most recent fiscal year, SyntekaBio reported revenue of $2M and EBITDA of ($8M).

SyntekaBio is unprofitable as of last fiscal year, with gross margin of 100%, EBITDA margin of (365%), and net margin of (507%).

See analyst estimates for SyntekaBio
LTMLast FY202320242025202620272028
Revenue$3M$2M$82K$80K$2M
Gross Profit-$2M$82K$80K$2M
Gross Margin-100%100%100%100%
EBITDA-($8M)($6M)($2M)($8M)
EBITDA Margin-(365%)(7504%)(2441%)(365%)
EBIT Margin(137%)(313%)(9948%)(11805%)(314%)
Net Profit($7M)($12M)($8M)($5M)($12M)
Net Margin(210%)(507%)(9236%)(5967%)(507%)

Financial data powered by Morningstar, Inc.

SyntekaBio Stock Performance

SyntekaBio has current market cap of $25M, and enterprise value of $21M.

Market Cap Evolution


SyntekaBio's stock price is $1.35.

SyntekaBio share price decreased by 6.1% in the last 30 days, and by 67.9% in the last year.

SyntekaBio has an EPS (earnings per share) of $-0.63.

See more trading valuation data for SyntekaBio
EVMarket CapPrice 1DPrice 1MPrice 3MPrice 12MEPS
$21M$25M-6.1%-6.1%-39.9%-67.9%$-0.63

Benchmark Trading Valuation Multiples by Industry

Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.

Start Free Trial

SyntekaBio Valuation Multiples

SyntekaBio trades at 6.0x EV/Revenue multiple, and (2.5x) EV/EBITDA.

See NTM and 2027E valuation multiples for SyntekaBio

EV / Revenue (LTM)


SyntekaBio Financial Valuation Multiples

As of June 2, 2026, SyntekaBio has market cap of $25M and EV of $21M.

SyntekaBio has a P/E ratio of (3.4x).

LTMLast FY202320242025202620272028
EV/Revenue6.0x9.2xn/mn/m9.2x
EV/EBITDA-(2.5x)(3.4x)(10.7x)(2.5x)
EV/EBIT(4.4x)(2.9x)(2.6x)(2.2x)(2.9x)
EV/Gross Profit-9.2xn/mn/m9.2x
P/E(3.4x)(2.1x)(3.3x)(5.1x)(2.1x)
EV/FCF-(2.9x)(1.8x)(1.9x)(2.9x)

Multiples above and below 250x are considered non-meaningful (n/m). Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Verified SyntekaBio Valuation Multiples

Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.

FactSetMorningstar
Start Free Trial

SyntekaBio Margins & Growth Rates

SyntekaBio grew revenue by 125% but net profit decreased by 88% in the last fiscal year.

In the most recent fiscal year, SyntekaBio reported gross margin of 100%, EBITDA margin of (365%), and net margin of (507%).

See estimated margins and future growth rates for SyntekaBio

SyntekaBio Margins

Last FY202420252026202720282029
Gross Margin100%100%100%-
EBITDA Margin(365%)(2441%)(365%)-
EBIT Margin(313%)(11805%)(314%)(27%)
Net Margin(507%)(5967%)(507%)(27%)
FCF Margin(313%)(13505%)(313%)-

SyntekaBio Growth Rates

FY+1/FY23/2424/2525/2626/2727/2828/29
Revenue Growth125%(2%)2737%125%
Gross Profit Growth-(2%)2737%-
EBITDA Growth-(68%)324%-
EBIT Growth(80%)16%(25%)(80%)
Net Profit Growth(88%)(37%)141%(88%)
FCF Growth-(7%)(34%)-

Data powered by FactSet, Inc. and Morningstar, Inc.

SyntekaBio Operational KPIs

SyntekaBio's revenue per employee in the last FY averaged $0.1M, while opex per employee averaged $0.2M for the same period.

Access forward-looking KPIs for SyntekaBio
Last FY202320242025202620272028
Revenue per Employee$0.1M---
Opex per Employee$0.2M---
S&M Expenses to Revenue78%765%1845%78%
G&A Expenses to Revenue36%540%1137%36%
R&D Expenses to Revenue67%2613%2430%67%
Opex to Revenue414%10048%11905%414%

Data powered by FactSet, Inc. and Morningstar, Inc.

Valuation Multiples Across 230+ Verticals

SyntekaBio Competitors

SyntekaBio competitors include Isofol Medical, Longeveron, Gensight Biologics, Pluri, Pasithea Therapeutics, Marker Therapeutics, Cellectar Biosciences, Vistagen Therapeutics, Xbrane Biopharma and Marinomed Biotech.

Most SyntekaBio public comparables operate across Biopharmaceuticals, BioTech and DeepTech.

EV/RevenueEV/EBITDA
Last FYLTM2027ELast FYLTM2027E
Isofol Medical--(2.2x)(2.0x)
Longeveron7.7x7.0x(0.4x)-
Gensight Biologics48.4x11.7x(3.6x)(2.4x)
Pluri36.9x-(2.2x)-
Pasithea Therapeutics--1.3x1.1x
Marker Therapeutics2.9x3.2x(0.8x)(0.8x)
Cellectar Biosciences--(0.8x)-
Vistagen Therapeutics(71.4x)(36.9x)0.6x-

This data is available for Pro users. Sign up to see all SyntekaBio competitors and their valuation data.

Start Free Trial

SyntekaBio VC Funding History

Before going public, SyntekaBio raised $33M in total equity funding, across 3 rounds.


SyntekaBio Funding Rounds

DateStageRaised FromRaisedValuationRev. MultipleDeal Summary
Jul-19Series CAltos Ventures; KB Securities; Saehan Venture Capital; Timewise Investment; Yuhan$17M--
May-18Series BAltos Ventures; Korea Development Bank; Smilegate Investment; Yozma Group Korea$11M-Syntekabio raised approximately $11.1 million in a Series B round on May 7, 2018, led by Smilegate Investment with participation from Altos Ventures, Korea Development Bank, and Yozma Group Korea. The company, founded in 2009 and based in Daejeon, South Korea with operations in Sunnyvale, United States, develops AI-driven drug discovery platforms. This was one of two funding rounds, with total equity funding of $11.12 million.
Jan-16Series AAltos Ventures$5M-Syntekabio is an AI-driven biotechnology company founded in 2009 that specializes in drug discovery and development using artificial intelligence and next-generation sequencing. The company operates a genomic database and AI-powered algorithmic platform for identifying drug candidates and biomarkers. Syntekabio announced a $5.6 million Series A funding round in 2016. The company has since grown to 61 employees as of December 2024 and has raised a total of $33.2 million across multiple funding rounds, including a post-IPO PIPE round in April 2024. The company competes in the AI-driven drug discovery space alongside competitors including NantHealth, BioAge Labs, and Perthera.

Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples

Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.

Start Free Trial

About SyntekaBio

When was SyntekaBio founded?SyntekaBio was founded in 2009.
Where is SyntekaBio headquartered?SyntekaBio is headquartered in South Korea.
How many employees does SyntekaBio have?As of today, SyntekaBio has over 41 employees.
Is SyntekaBio publicly listed?Yes, SyntekaBio is a public company listed on Korea Exchange.
What is the stock symbol of SyntekaBio?SyntekaBio trades under 226330 ticker.
When did SyntekaBio go public?SyntekaBio went public in 2019.
Who are competitors of SyntekaBio?SyntekaBio main competitors include Isofol Medical, Longeveron, Gensight Biologics, Pluri, Pasithea Therapeutics, Marker Therapeutics, Cellectar Biosciences, Vistagen Therapeutics, Xbrane Biopharma, Marinomed Biotech.
What is the current market cap of SyntekaBio?SyntekaBio's current market cap is $25M.
What is the current revenue of SyntekaBio?SyntekaBio's last 12 months revenue is $3M.
What is the current revenue growth of SyntekaBio?SyntekaBio revenue growth (NTM/LTM) is 48%.
What is the current EV/Revenue multiple of SyntekaBio?Current revenue multiple of SyntekaBio is 6.0x.
Is SyntekaBio profitable?No, SyntekaBio is not profitable.
What is the current net income of SyntekaBio?SyntekaBio's last 12 months net income is ($7M).
How many companies SyntekaBio has acquired to date?SyntekaBio hasn't acquired any companies yet (or none have been disclosed publicly).
In how many companies SyntekaBio has invested to date?SyntekaBio hasn't invested in any companies yet (or none have been disclosed publicly).

See public comps similar to SyntekaBio

Lists including SyntekaBio

Start Your
Free Trial Today

Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.

Start Trial